For GRN-low patients, combined chemo-immunotherapy offers significant survival benefits, while for GRN-high patients, novel approaches targeting the tumor microenvironment or GRN-driven pathways may be required to overcome resistance. This evidence concerns the gene GRN and neoplasm.